Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03192059
Title Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Ghent
Indications

endometrial carcinoma

cervix carcinoma

uterine corpus sarcoma

Therapies

Aspirin + Cyclophosphamide + Pembrolizumab + Vitamin D

Age Groups: senior | adult
Covered Countries BEL


No variant requirements are available.